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Wilms tumour occurring in a patient with osteopathia striata
with cranial sclerosis: A still unsolved biological question
To the Editor:
Osteopathia striata with cranial sclerosis (OSCS,MIM#300373) is a
rare X-linked dominant skeletal dysplasia characterised by linear stria-
tions in the metaphyseal region of the long bones and pelvis in combi-
nation with cranial sclerosis owing to increased osteoblast activity.1,2
The rarity and heterogeneity of its phenotype makes a diagnosis of
OSCS challenging, leading to the risk that it can actually be missed for
many years. Jenkins et al. found that OSCS is caused by germline dele-
tions/mutations of the AMER1 gene (MIM#300647, NM_152424.4)
located on Xq11.2.3 Somatic mutations in AMER1 are found in 7–29%
ofWilms tumours (WT).4–7
To date, and to the best of our knowledge, just five cases of paedi-
atric tumours, fourWTandonehepatoblastoma, havebeen reported in
patientswithOSCS8–10 despite two large studies investigating cohorts
of patients (including adults) with OSCS did not find an increased risk
of cancer.3,11
Herein, we report a clinical and molecular description of an addi-
tional girl affected byOSCSwho developed aWT.
The girl was born at 35 weeks of gestation to healthy noncon-
sanguineous parents. At her birth, macrocephaly, a prominent fore-
head, retrognathia, anteverted nares, hypertelorism and pectus exca-
vatum were all observed. The neonatal audiometry was normal. The
brain magnetic resonance imaging was unremarkable except for the
evidence of macrocephaly. During follow-up, a mild intellectual dis-
ability (ID) became evident in the girl, particularly in speech ability.
Later, at the age of 4, the patient began to experience a painless
rapid increase in abdominal volume. A computed tomography (CT)
scan showedacapsulatedpolycyclic hypo-vascularised retroperitoneal
mass with necrotic areas, compatible with a renal tumour. A chest CT
was also performed and resulted negative for metastases, but intrigu-
ingly, the chest X-ray inadvertently revealed longitudinal sclerotic stri-
ations in the humeral metaphysis (Figure 1). Similarly, the radiographs
of her long bones demonstrated prominent linear sclerotic striations in
the metaphyses and epiphyses and fan-like striations of the iliac crest
(Figure 1).
The girl underwent a core needle biopsy of the lesion, which con-
firmed our suspicion ofWT. After this diagnosis, the girl started neoad-
juvant chemotherapy according to the contemporary national proto-
col. At nephrectomy, pathology inspection revealed a mixed epithe-
lial and blastemal WT, with no associated nephrogenic rests, stage
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III. Treatment was then completed with adjuvant chemotherapy and
abdominal radiotherapy.
At the same time, our geneticists raised the suspicion ofOSCSbased
on the facial dysmorphisms, macrocephaly, ID, and the typical meta-
physeal striations of her long bones. We performed a clinical exome
sequencing (SOPHiA GENETICS) on the patient’s DNA extracted from
her peripheral blood, which revealed a heterozygous nonsense muta-
tion c.1072C>Tp. (Arg358Ter) in the AMER1 gene. The mutation was
confirmed by Sanger sequencing and was compatible with diagnosis of
OSCS, and was demonstrated to be de novo studying parents’ periph-
eral blood DNA.
This mutation has been previously reported in other cases with
OSCS.3,11 Sanger sequencing performed on tumour DNA obtained
from a single formalin-fixed paraffin embedded sample disclosed that
the AMER1 wild-type allele was lost in the tumour; analysis of the
tumour cDNA from the same block showed that the mutant allele was
expressed (Figure S1). No further genetic tests on the girl’s tumour
DNA have been performed. Our patient is currently 7 years old and in
complete remission, 2 years after the end of treatment.
To the best of our knowledge, among previously reported OSCS
patients who developed a childhood cancer, a genetic investigation
of AMER1 in the tumour was performed only in two of those cases,
one WT and one hepatoblastoma. In both cases, the authors reported
retention of heterozygosity for the germline AMER1 mutation.9,10 In
our patient, we demonstrated that the AMER1 wild-type allele was
lost in the tumour, which expressed the mutant allele. Ours is the only
patient with OSCS where tumour cDNA was investigated, whereas
the determination of the presence of theWTX mutated/deleted allele
on the active or inactive X chromosome (Xa and Xi, respectively) in
tumours from female patients with OSCS would be important. Bach
et al. proposed a likely association betweenOSCS andWT.8
The prevalence of OSCS is estimated in less than one per million
with fewer than 100 cases reported in the literature worldwide. How-
ever, these data are probably underestimated, because we should also
take into consideration the likelihood of undiagnosed or misdiagnosed
cases due to the heterogeneity of OSCS phenotypes. Noteworthy, also
our patient was diagnosed with OSCS only after performing chest X-
ray forWT.Consequently, calculationof theprobability to present both
phenotypes (OSCS and WT) based on their related reported preva-
lence could not precisely estimate theprobability of the co-occurrence.
Moreover, literature data demonstrated that in female patients
with WT, AMER1 deletions/mutations can occur on both the Xa and
Xi4,7; suggesting that AMER1 alteration is not an essential and early
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mutation needed to driveWT tumourigenesis, but rather a later event
with unclear clinical relevance12; and showed thatWtx deletion inmice
causes neonatal lethality, somatic overgrowth, and malformations of
multiple mesenchyme-derived tissues, but notWT.13
All these considerations suggest caution in drawing any conclusion
about a possible association between OSCS and WT and underline
the need to deeply investigate molecular anomalies that occur in the
tumours of OSCS patients to disclose the underlying mechanisms and
the role of their germlinemutation.
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